9 completed. 7 Phase 3, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 7 |
| Phase 2 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Sankyo Pharma Gmbh: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary - Essential Hypertension | Phase 4 | Completed | Sankyo Pharma Gmbh | 694 | 2006-03-01 | 2010-12-10 |
| Amlodipine as add-on to Olmesartan in Hypertension olmesartan medoxomil, amlodipine - Essential Hypertension | Phase 3 | Completed | Sankyo Pharma Gmbh | 429 | 2005-04-01 | 2018-12-24 |
| Olmesartan as an add-on to Amlodipine in Hypertension olmesartan medoxomil, amlodipine, hydrochlorothiazide - Essential Hypertension | Phase 3 | Completed | Sankyo Pharma Gmbh | 632 | 2005-04-01 | 2018-12-24 |
| Olmesartan Medoxomil in Diabetes Mellitus Olmesartan medoxomil, Placebo Tablets - Diabetes Mellitus, Type 2, Cardiovascular Disease | Phase 3 | Completed | Sankyo Pharma Gmbh | 4449 | 2004-10-01 | 2010-01-20 |
| Olmesartan Medoxomil in Hypertension and Renal Impairment Olmesartan medoxomil, Losartan, Furosemide oral tablets - Essential Hypertension, Renal Impairment | Phase 3 | Completed | Sankyo Pharma Gmbh | 393 | 2003-08-01 | 2010-10-14 |
| Olmesartan Medoxomil and Diabetic Nephropathy Olmesartan medoxomil, Losartan - Type 2 Diabetes Mellitus, Diabetic Nephropathy | Phase 3 | Completed | Sankyo Pharma Gmbh | 300 | 2003-05-01 | 2006-10-09 |
| Efficacy and Safety of Pactimibe in Patients With Atherosclerosis Pactimibe - Atherosclerosis | Phase 2 | Completed | Sankyo Pharma Gmbh | 200 | 2002-09-01 | 2007-03-28 |
| Olmesartan in Essential Hypertension placebo, olmesartan medoxomil, olmesartan medoxomil oral tablets, hydrochlorothiazide oral tablets - Essential Hypertension | Phase 3 | Completed | Sankyo Pharma Gmbh | 2333 | 2002-01-01 | 2008-04-29 |
| Olmesartan Medoxomil in Atherosclerosis Olmesartan medoxomil, Atenolol, Hydrochlorothiazide - Essential Hypertension, Atherosclerotic Cardiovascular Disease | Phase 3 | Completed | Sankyo Pharma Gmbh | 165 | 2001-11-01 | 2007-12-14 |
Essential Hypertension (6) · Atherosclerosis (2) · Diabetes Mellitus, Type 2 (2) · Kidney Diseases (2) · Cardiovascular Diseases (1) · Diabetic Nephropathies (1) · Hypertension (1) · Proteinuria (1) · Renal Insufficiency (1)
Olmesartan Medoxomil (8) · Hydrochlorothiazide (4) · Amlodipine (3) · Losartan (2) · Atenolol (1) · Furosemide (1) · pactimibe (1)
Germany (9) · Netherlands (3) · Austria (2) · Italy (2) · Portugal (2) · Spain (2) · Switzerland (2) · United Kingdom (2) · Belgium (1) · Czechia (1) · Estonia (1) · France (1) · Poland (1) · Slovakia (1)
Peter Brommer, MD (2) · Anthony Heagerty, MD (1) · H Haller, MD (1) · P U Witte, MD, PhD, FFPM (1) · P. U. Witte, MD, PhD (1) · Prof. Hermann Haller, MD (1) · Prof. Klaus O Stumpe, MD (1) · Prof. Michael Bohm, MD (1)
PMID 19499960, PMID 19876613, PMID 21150933, PMID 21388309, PMID 22418908, PMID 24772521, PMID 29035939, PMID 36975019, PMID 37565307
2005 (1)